2017•Europe PMC (PubMed Central)Requires access

Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines

Chuong Ho, Sarah Jones

Abstract

This Rapid Response report aims to review the clinical effectiveness and safety of 3- month injectable paliperidone palmitate (PP3M) for schizophrenia compared with once-monthly injectable formulation (PP1M) and placebo in the treatment of adults with schizophrenia. Evidence-based guidelines regarding the use of 3-month injectable paliperidone palmitate for the adults with schizophrenia will also be examined.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Paliperidone Palmitate, Schizophrenia (object-oriented programming), Paliperidone, Medicine, Placebo, Psychiatry, Clinical trial, Antipsychotic